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Letter to the Editor 
 
Opportunities lost may be the greatest cost of CPE outbreaks 
 
Sir, 
Carbapenemase Producing Enterobacteriaceae (CPE) outbreaks are reported 
internationally with increasing frequency, often associated with antimicrobial-
resistant infections that are challenging to treat.1, 2 It is unsurprising, therefore, that 
considerable efforts are being made to understand both the sources and 
epidemiology of these incidences.3-5 Further focus has been placed on calculating 
the economic costs of these outbreaks. Notably, Bartsch and colleagues found that 
the financial burden of CPE in the USA was higher than that attributable to many 
chronic and acute diseases.6  Otter et al. performed a comprehensive audit of costs 
arising from a 40 patient CPE-outbreak across five hospitals in the UK, reporting 
both actual and opportunity costs that accrued in 2015.7   
Using an approach analogus to Otter’s, we completed a retrospective review of 
accrued costs relating to a comparable 2015 CPE outbreak involving 27 patients in 
Limerick (Ireland). Although less comprehensive than the UK study, and focused 
somewhat more on patient experiences of CPE diagnosis,8 the direct economic 
comparison on an almost like for like basis (similar patient numbers) was insightful.  
Across shared parameters, for example anti-infective costs, screening, contact 
precautions, ward monitors, and hydrogen peroxide vapour decontamination, the 
Irish costs amounted to €1,375,000, representing €835,000 more than the UK costs, 
despite 33% less Irish patient involvement. Forensic accounting may determine 
where the greatest disparities in cost are, although it is apparent that pricing of 
drugs, consumables and decontaminiation are reasonably similar.  
Otter et al. described reduced capacity to perform elective surgical procedures and 
840 bed-day closures as the largest contributors to loss of hospital income 
subsequent to their CPE outbreak, reflecting losses of €349,000 and €244,000, 
respectively.7 In Limerick, 473 lost bed-days were recorded. Unlike UK hospitals, we 
are unable to attribute loss of income specifically. However, the impact of such 
reduced capacity is evident, with official Irish Government statistics reporting hospital 















now endemic in many Irish hospitals2, it seems reasonable to predict ongoing 
budgetary requirements, dedicated isolation facilites, and loss of bed-days. It is the 
latter that concerns us most, as delayed access to hospitalisation increases time to 
treatment, and reduces those critical windows of opportunity in which elective or 
acute care can be most effective.   
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